| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
We established a method to generate erythropoietin (EPO)-producing cells from human induced pluripotent stem cells (hiPSCs) by modifying previously reported hepatic differentiation protocols. These cells showed increased EPO expression and secretion in response to low oxygen conditions, prolyl hydroxylase domain-containing enzymes inhibitors or insulin-like growth factor-1. The EPO protein secreted from hiPSC-derived EPO-producing cells (hiPSC-EPO cells) induced the erythropoietic differentiation of umbilical cord blood progenitors in vitro. Furthermore, transplantation of hiPSC-EPO cells improved renal anemia in adenine-induced CKD mice. In conclusion, hiPSC-EPO cells may be a useful tool for clarifying the mechanisms of EPO production and provide a novel therapeutic agent for anemia.
|
